Diabetes

ASN: Bardoxolone methyl no benefit in T2DM, stage 4 CKD

(HealthDay)—Bardoxolone methyl does not reduce the risk of end-stage renal disease (ESRD) or cardiovascular death in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, according to a study published ...

Cardiology

Race, ethnicity has no impact on long-term mortality in T2DM

(HealthDay)—For adults with type 2 diabetes and coronary artery disease, race/ethnicity has no significant impact on the long-term risk of death, according to a study published in the Nov. 1 issue of The American Journal ...

Diabetes

Autonomic dysfunction predicts cardiovascular events in T2DM

(HealthDay)—Autonomic dysfunction predicts cardiovascular events for patients with type 2 diabetes; and, the presence of cardiovascular autonomic neuropathy (CAN) predicts severe hypoglycemia (SH) in type 2 diabetes, according ...

Cardiology

Cardiac imaging not useful for screening healthy athletes

(HealthDay)—The prognostic value of using cardiac imaging to screen healthy athletes is uncertain, according to research published in the Sept. 1 issue of the Journal of the American College of Cardiology: Cardiovascular ...

Cardiology

CDC: 200,000 avoidable deaths from cardiovascular disease

(HealthDay)—There were about 200,000 avoidable deaths from cardiovascular disease in 2010 in the United States, with deaths occurring disproportionately among those over 65 years old, males, non-Hispanic blacks, and those ...

page 37 from 40